3.17 Similar Rates of Invasive Fungal Disease in CLL and ‘High-Risk' Acute Myeloid Leukaemia/Allogeneic Transplant Patients

2011 ◽  
Vol 11 ◽  
pp. S207-S208
Author(s):  
Shamzah Araf ◽  
Dimitris A. Tsitsikas ◽  
Jan Stevenson ◽  
Samir G. Agrawal
2021 ◽  
Author(s):  
Daniel K. Yeoh ◽  
Andrew S. Moore ◽  
Rishi S. Kotecha ◽  
Adam W. Bartlett ◽  
Anne L. Ryan ◽  
...  

Mycoses ◽  
2010 ◽  
Vol 54 (4) ◽  
pp. e92-e98 ◽  
Author(s):  
Christina T. Rieger ◽  
Saskia Huppmann ◽  
Lisa Peterson ◽  
Heidi Rieger ◽  
Helmut Ostermann

2019 ◽  
Vol 102 (3) ◽  
pp. 218-226
Author(s):  
Marie Warny ◽  
Jens Helby ◽  
Henrik Sengeløv ◽  
Børge G. Nordestgaard ◽  
Henrik Birgens ◽  
...  

Oncoreview ◽  
2016 ◽  
Vol 6 (4) ◽  
pp. 0-0
Author(s):  
Jan Styczyński

This paper reports on diagnostic and therapeutic management of pulmonary invasive fungal disease (IFD) in a child with relapsed acute myeloid leukaemia, undergoing chemotherapy followed by hematopoietic stem cell transplantation. Surgical management with resection of the involved lung tissue was based on the location of fungal infiltrates close to large circulatory vessels. After examination of resected pulmonary tissue, a diagnosis of proven IFD was done. This case report is an example that aspergillosis is usually the cause for pulmonary IFD. Pharmacotherapy of pulmonary IFD should be based on compounds with good penetration to lung tissue: amphotericin B lipid form or voriconazole.


Sign in / Sign up

Export Citation Format

Share Document